20. Adrenoleukodystrophy Clinical trials / Disease details


Clinical trials : 53 Drugs : 88 - (DrugBank : 31) / Drug target genes : 23 - Drug target pathways : 123

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02961803
(ClinicalTrials.gov)
October 20149/11/2016MD1003-AMN MD1003 in AdrenomyeloneuropathyMD1003 in Adrenomyeloneuropathy : a Randomized Double Blind Placebo Controlled StudyAdrenomyeloneuropathy;Adrenoleukodystrophy;AMNDrug: MD1003 100 mg capsule;Drug: PlaceboMedDay Pharmaceuticals SANULLCompleted18 Years60 YearsMale67Phase 2/Phase 3France;Germany;Spain
2EUCTR2014-000698-38-ES
(EUCTR)
13/08/201413/06/2014MD1003 IN ADRENOMYELONEUROPATHYMD1003 IN ADRENOMYELONEUROPATHY: A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY - MD1003-AMN Adrenomyeloneuropathy
MedDRA version: 17.0;Level: LLT;Classification code 10069075;Term: Adrenomyeloneuropathy without cerebral involvement;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: biotin
Product Code: MD1003
INN or Proposed INN: D-BIOTIN
MEDDAY SASNULLNot RecruitingFemale: no
Male: yes
60Phase 2;Phase 3Spain